Literature DB >> 33959878

Burden of Herpes Zoster in Adult Patients with Underlying Conditions: Analysis of German Claims Data, 2007-2018.

Manuel Batram1, Julian Witte2, Magdalena Schwarz3, Johannes Hain3, Bernhard Ultsch3, Maren Steinmann2, Amit Bhavsar4, Peter Wutzler5, Carl-Peter Criée6, Christiane Hermann7, Klaus Wahle8, Martin Füchtenbusch9,10, Wolfgang Greiner2.   

Abstract

INTRODUCTION: Several chronic underlying conditions (UCs) are known to be risk factors for developing herpes zoster (HZ) and to increase the severity of HZ and its risk of recurrence. The aim of this study was to investigate the incidence and recurrence of HZ in adult patients with one or multiple UCs.
METHODS: A retrospective cohort study based on claims data representing 13% of the statutory health insurance population from 2007 to 2018 in Germany was performed. Patients aged ≥ 18 years were included when at least one of the following UCs was diagnosed: asthma, chronic heart failure, chronic obstructive pulmonary disease (COPD), coronary heart disease (CHD), depression, diabetes mellitus type 1 or 2, and rheumatoid arthritis (RA). Exact matching was used to account for differences in the distribution of age and sex between the case and matched control cohorts. Multi-morbidity was considered in sensitivity analyses by analyzing patients with only one UC.
RESULTS: Patients with asthma, CHD, COPD, depression, and RA had, on average, a 30% increased risk of developing acute HZ compared to patients without any UC. RA was found to have the highest odds ratio among these conditions, varying from 1.37 to 1.57 for all age groups. Patients with depression also showed a high risk of developing HZ. Analysis of recurrence indicated that patients with at least one UC in the age groups 18-49 years and 50-59 years had the highest risk for a recurrent HZ. After experiencing a first recurrence, patients, regardless of age group, had a two- to threefold higher risk for a second recurrence.
CONCLUSION: This study of representative claims data shows a higher HZ incidence and recurrence frequency in patients with UCs. These results provide relevant information for national health care guidelines and disease management programs.

Entities:  

Keywords:  Claims data; Herpes zoster; Incidence; Recurrence; Underlying conditions

Year:  2021        PMID: 33959878     DOI: 10.1007/s13555-021-00535-7

Source DB:  PubMed          Journal:  Dermatol Ther (Heidelb)


  41 in total

Review 1.  Clinical practice. Herpes zoster.

Authors:  John W Gnann; Richard J Whitley
Journal:  N Engl J Med       Date:  2002-08-01       Impact factor: 91.245

2.  Acute pain in herpes zoster and its impact on health-related quality of life.

Authors:  Jennifer Katz; Edith M Cooper; Robert R Walther; Eugene W Sweeney; Robert H Dworkin
Journal:  Clin Infect Dis       Date:  2004-07-19       Impact factor: 9.079

3.  Incidence of herpes zoster and its complications in Germany, 2005-2009.

Authors:  Kathrin Hillebrand; Hélène Bricout; Renate Schulze-Rath; Tania Schink; Edeltraut Garbe
Journal:  J Infect       Date:  2014-09-16       Impact factor: 6.072

4.  European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 1: Diagnosis.

Authors:  R N Werner; A F Nikkels; B Marinović; M Schäfer; M Czarnecka-Operacz; A M Agius; Z Bata-Csörgő; J Breuer; G Girolomoni; G E Gross; S Langan; R Lapid-Gortzak; T H Lesser; U Pleyer; J Sellner; G M Verjans; P Wutzler; C Dressler; R Erdmann; S Rosumeck; A Nast
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-11-02       Impact factor: 6.166

5.  [Herpes zoster and postherpetic neuralgia - prevention by vaccination?].

Authors:  P Wutzler
Journal:  Dtsch Med Wochenschr       Date:  2009-04-07       Impact factor: 0.628

6.  Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom.

Authors:  A Gauthier; J Breuer; D Carrington; M Martin; V Rémy
Journal:  Epidemiol Infect       Date:  2008-05-09       Impact factor: 2.451

Review 7.  Herpes zoster (shingles) and postherpetic neuralgia.

Authors:  Priya Sampathkumar; Lisa A Drage; David P Martin
Journal:  Mayo Clin Proc       Date:  2009-03       Impact factor: 7.616

8.  Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany.

Authors:  Bernhard Ultsch; Ingrid Köster; Thomas Reinhold; Anette Siedler; Gérard Krause; Andrea Icks; Ingrid Schubert; Ole Wichmann
Journal:  Eur J Health Econ       Date:  2012-12-28

9.  European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment.

Authors:  R N Werner; A F Nikkels; B Marinović; M Schäfer; M Czarnecka-Operacz; A M Agius; Z Bata-Csörgő; J Breuer; G Girolomoni; G E Gross; S Langan; R Lapid-Gortzak; T H Lesser; U Pleyer; J Sellner; G M Verjans; P Wutzler; C Dressler; R Erdmann; S Rosumeck; A Nast
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-11-02       Impact factor: 6.166

10.  Impact of herpes zoster and postherpetic neuralgia on the quality of life of Germans aged 50 or above.

Authors:  Desmond Curran; Ruprecht Schmidt-Ott; Ulf Schutter; Jörg Simon; Anastassia Anastassopoulou; Sean Matthews
Journal:  BMC Infect Dis       Date:  2018-10-03       Impact factor: 3.090

View more
  2 in total

1.  Association between vitamin D and incident herpes zoster: a UK Biobank study.

Authors:  Liang-Yu Lin; Rohini Mathur; Amy Mulick; Liam Smeeth; Sinéad M Langan; Charlotte Warren-Gash
Journal:  Br J Gen Pract       Date:  2022-04-04       Impact factor: 6.302

2.  Baculovirus Display of Varicella-Zoster Virus Glycoprotein E Induces Robust Humoral and Cellular Immune Responses in Mice.

Authors:  Wenhui Xue; Tingting Li; Sibo Zhang; Yingbin Wang; Minqing Hong; Lingyan Cui; Hong Wang; Yuyun Zhang; Tingting Chen; Rui Zhu; Zhenqin Chen; Lizhi Zhou; Rongwei Zhang; Tong Cheng; Qingbing Zheng; Jun Zhang; Ying Gu; Ningshao Xia; Shaowei Li
Journal:  Viruses       Date:  2022-08-16       Impact factor: 5.818

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.